title: Future of fixed-dose longacting β2-agonist and antimuscarinic combination therapy in COPD.
authors: Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 USA. Electronic address: dtashkin@mednet.ucla.edu.
authors: Donald P
authors: DP
authors: Tashkin
mesh_terms: D000420:Albuterol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000730:Androstadienes / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D000068297:Fluticasone-Salmeterol Drug Combination; D005938:Glucocorticoids / Q000627:therapeutic use*; D006024:Glycopyrrolate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007189:Indans / Q000627:therapeutic use*; D008297:Male; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D015363:Quinolones / Q000627:therapeutic use*; D013566:Sympathomimetics / Q000627:therapeutic use*
chemical_list: D000730:Androstadienes; D001993:Bronchodilator Agents; D004338:Drug Combinations; D000068297:Fluticasone-Salmeterol Drug Combination; D005938:Glucocorticoids; D007189:Indans; D015363:Quinolones; D013566:Sympathomimetics; C554862:indacaterol-glycopyrronium combination; D000420:Albuterol; D006024:Glycopyrrolate